Afficher la notice abrégée

dc.contributor.authorSchäfer, Thomas
dc.contributor.authorÖzalp, Veli C.
dc.contributor.authorÖzalp, Veli C.
dc.contributor.authorSchäfer, Thomas
dc.date.accessioned2025-03-07T18:24:10Z
dc.date.available2025-03-07T18:24:10Z
dc.date.issued2012
dc.date.submitted2019-10-04 14:28:10
dc.date.submitted2020-04-01T14:07:00Z
dc.date.submitted2016-08-01 23:55
dc.date.submitted2019-10-04 14:28:10
dc.date.submitted2020-04-01T14:07:00Z
dc.date.submitted2016-12-31 23:55:55
dc.date.submitted2019-10-04 14:28:10
dc.date.submitted2020-04-01T14:07:00Z
dc.identifier612587
dc.identifierOCN: 1030822012
dc.identifierhttp://library.oapen.org/handle/20.500.12657/32346
dc.identifier.urihttps://doab-dev.siscern.org/handle/20.500.12854/161849
dc.description.abstractDrug delivery systems traditionally relied on passive diffusion mechanisms for targeting and releasing of therapeutically active molecules. The major problems associated with traditional delivery are poor specificity and dose-limited toxicity. Nanoparticles have found applicability in the development of novel drug delivery systems by easily overcoming toxicity problem. However, specificity of delivery has remained as a challenge. Developments in the methods of reaching to targeted tissue have lead to new and improved drug delivery platforms. Recently, active targeting has been incorporated by cell specific ligands such as antibodies, lectins, growth factor receptors. More recently, aptamers gained popularity in construction of novel actively targeted drug delivery systems (Ozalp et al., 2011). Considerable proportions of aptamer-based delivery systems have been incorporated to a variety of nanomaterials in order to improve their specific targeting properties (Chen et al., 2011; Zhou et al., 2011).
dc.languageEnglish
dc.rightsopen access
dc.subject.classificationthema EDItEUR::P Mathematics and Science::PD Science: general issues
dc.subject.otherdrug delivery
dc.subject.othernanoparticles
dc.subject.otherdrug delivery
dc.subject.othernanoparticles
dc.subject.otherAptamer
dc.subject.otherProtein
dc.titleChapter 7 Aptamer-Nanoparticle Bioconjugates for Drug Delivery
dc.typechapter
oapen.identifier.doi10.5772/35188
oapen.relation.isPublishedBy035ecc65-6737-43cf-a13a-6bdf67ce01f4
oapen.relation.isPartOfBookThe Delivery of Nanoparticles
oapen.relation.isFundedByFP7 Ideas: European Research Council
oapen.relation.isFundedBy7292b17b-f01a-4016-94d3-d7fb5ef9fb79
oapen.collectionEuropean Research Council (ERC)
oapen.collectionEU collection
oapen.grant.number209842
oapen.grant.programFP7
dc.relationisFundedBy7292b17b-f01a-4016-94d3-d7fb5ef9fb79
dc.chapternumber1


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

open access
Excepté là où spécifié autrement, la license de ce document est décrite en tant que open access